Discover how a structural breakthrough in the chikungunya virus is opening new avenues for antiviral drug development and targeted therapies.

A new study, published recently in Nature Communications, offers the first-ever map of which parts of the Chikungunya virus ...

Confirming a Cell Structure’s Role Dr. Kielian and colleagues discovered the presence of ILEs in chikungunya-infected cells several years ago, but it wasn’t clear whether the structures ...

More than a quarter million cases of chikungunya virus have surfaced in South America this year. The virus can cause debilitating joint pain. Now the U.S. FDA has approved a new vaccine.

The FDA on Thursday announced approval of Ixchiq, the first chikungunya vaccine, for anyone 18 and older who has a risk of being exposed to the mosquito-borne virus.

The U.S. Food and Drug Administration on Thursday approved the first vaccine against chikungunya virus, a disease that is primarily transmitted to people through infected mosquito bites. The ...

Challenges to Clinical Trials & Deployment of a Chikungunya Vaccine Vaccination is the most cost-effective means of protecting the at-risk populations in CHIK-endemic developing countries.

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

If approved, Valneva’s shot could be the first approved for chikungunya, a virus transmitted by mosquitoes with similar symptoms to dengue and Zika, including severe joint pain that can last years.

CDC is currently investigating five hospitalizations for cardiac or neurologic events among people 65 and older following vaccination with IXCHIQ, a vaccine approved to help prevent chikungunya in ...

Health Mosquito-borne disease has cost the world billions, researchers say Scientists say there were 18.7 million chikungunya cases that exacted a total cost of nearly $50 billion over a decade.

The virus-like particle chikungunya vaccine received accelerated approval from the FDA in February, and is one of two single-dose vaccines to prevent disease caused by the chikungunya virus.